UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):   October 4, 2012

 

Marina Biotech, Inc.
(Exact name of registrant as specified in its charter)

 

Delaware   000-13789   11-2658569
(State or other jurisdiction    (Commission    (I.R.S. Employer
of incorporation)   File Number)   Identification No.)
         
3830 Monte Villa Parkway, Bothell,
Washington
      98021
 (Address of principal executive offices)        (Zip Code)

 

Registrant’s telephone number, including area code: 425-908-3600

 

N/A

Former name or former address, if changed since last report 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 1.01 Entry Into a Material Definitive Agreement.

 

Amendment to Note Purchase Agreement

 

On October 4, 2012, Marina Biotech, Inc. (the “Company”) entered into a Fourth Amendment (the “Fourth Amendment”) to that certain Note and Warrant Purchase Agreement (as amended from time to time, the “Purchase Agreement”) dated as of February 10, 2012 among the Purchasers identified on the signature pages thereto (the “Purchasers”), the Company, MDRNA Research, Inc., a wholly-owned subsidiary of the Company (“Research”), and Cequent Pharmaceuticals, Inc., a wholly-owned subsidiary of the Company (“Cequent” and, together with the Company and Research, the “Companies”). Pursuant to the Fourth Amendment, the parties amended the Third Amendment to the Purchase Agreement to remove the obligation set forth therein that the Companies pay to the Purchasers all sums received from the sale of surplus equipment by the Companies (net of expenses).

 

As consideration for the Fourth Amendment, the Company issued to the Purchasers warrants to purchase up to an aggregate of 1,035,715 shares of the common stock of the Company (the “Warrants”). The Warrants will have an initial exercise price of $0.28 per share, which is subject to adjustment (including as a result of subsequent financings completed on or prior to June 30, 2014), will be exercisable for a period of five years beginning six months and one day following the issuance of the Warrants, and otherwise have substantially the same terms and conditions as the warrants that were issued to the Purchasers upon the closing of the Purchase Agreement.

 

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Fourth Amendment, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K.

 

Amendment of Lease

 

On October 5, 2012, the Company entered into a Lease Termination Agreement (the “Termination Agreement”), effective as of October 1, 2012, with Ditty Properties Limited Partnership (“Landlord”) with respect to that certain Lease Agreement dated March 1, 2006 between the Company and Landlord (as amended from time to time, the “Lease”) regarding the Company’s facilities located at 3830 Monte Villa Parkway, Bothell, WA. Pursuant to the Termination Agreement, the Company shall immediately pay to Landlord $155,000 as rent for the premises for the month of October 2012. Thereafter, the Company’s obligation to pay further rent under the Lease will be satisfied through the Irrevocable Letter of Credit that the Company established to support its obligations under the Lease (the “Letter of Credit”). Landlord will draw the amount of each month’s rent by drawing on the Letter of Credit on or about the first day of each month from November 2012 through February 2013, with Landlord drawing the entire remaining amount available to be drawn on the Letter of Credit when it draws the February 2013 rent. The Company will have no obligation to replenish the Letter of Credit for amounts drawn by Landlord. The Lease will terminate effective on March 1, 2013; provided that prior to March 1, 2013 Landlord may terminate the Lease on 10 days’ prior written notice, in which event Landlord shall be entitled to immediately draw all remaining amounts under the Termination Agreement on the Letter of Credit.

 

As additional consideration for the Termination Agreement, the Company agreed to issue 1,500,000 shares of its common stock to Landlord contingent upon and immediately prior to the first to occur of any of the following events: (i) the closing by the Company of an equity financing in a transaction or series of related transactions where such financing yields gross proceeds to the Company of at least $4 million in the aggregate, including amounts converted under any convertible promissory notes; (ii) a merger of the Company with or into another entity if the combined market capitalization of the merging entities is at least $18 million or, if not, upon the market capitalization of the Company as the surviving entity of a merger being at least $18 million at any time after the merger; (iii) a sale of all or substantially all of the Company’s assets; or (iv) a sale of the Company’s stock after which sale a majority of the outstanding equity of the Company is held by persons or entities who were not shareholders of the Company prior to the sale.

 

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Termination Agreement, a copy of which is attached as Exhibit 10.2 to this Current Report on Form 8-K.

 

 
 

 

Item 3.02 Unregistered Sales of Equity Securities.

 

Issuance of Warrants to Noteholders

 

In connection with the Fourth Amendment described under the heading “Amendment to Note Purchase Agreement” in Item 1.01 above, the Company issued the Warrants to the Purchasers. The Company is issuing the Warrants and the shares issuable upon exercise thereof in reliance on the exemption from registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D promulgated thereunder.

 

Issuance of Common Stock to Landlord

 

In connection with the Termination Agreement described under the heading “Amendment of Lease” in Item 1.01 above, the Company agreed to issue 1,500,000 shares of its common stock to Landlord. The Company offered these shares in reliance on the exemption from registration afforded by Section 4(2) of the Securities Act.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
     
10.1   Fourth Amendment to Note and Warrant Purchase Agreement and Secured Promissory Notes, dated October 4, 2012, among Marina Biotech, Inc., Cequent Pharmaceuticals, Inc., MDRNA Research, Inc., and the purchasers identified on the signature pages thereto.
     
10.2   Lease Termination Agreement, effective as of October 1, 2012, by and between Ditty Properties Limited Partnership and Marina Biotech, Inc.

 

 

  

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Marina Biotech, Inc.
   
October 9, 2012 By: /s/ J. Michael French
  Name: J. Michael French
  Title: Chief Executive Officer

 

 
 

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
10.1   Fourth Amendment to Note and Warrant Purchase Agreement and Secured Promissory Notes, dated October 4, 2012, among Marina Biotech, Inc., Cequent Pharmaceuticals, Inc., MDRNA Research, Inc., and the purchasers identified on the signature pages thereto.
     
10.2   Lease Termination Agreement, effective as of October 1, 2012, by and between Ditty Properties Limited Partnership and Marina Biotech, Inc.

 

 

  

 

 

EXECUTION

 

FOURTH AMENDMENT TO

NOTE AND WARRANT PURCHASE AGREEMENT

and SECURED PROMISSORY NOTES

 

This Fourth Amendment (as amended, restated, supplemented or otherwise modified from time to time, the “ Fourth Amendment ”) dated as of October 4, 2012, among Marina Biotech, Inc., a Delaware corporation (the “ Company ”), MDRNA Research, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“ Research ”), and Cequent Pharmaceuticals, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“ Cequent ” and, together with the Company and Research, the “ Companies ”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “ Purchaser ” and collectively the “ Purchasers ”), amends (i) that certain Note and Warrant Purchase Agreement (as amended from time to time, the “ Purchase Agreement ”), dated as of February 10, 2012, among the Companies and the Purchasers and (ii) the Secured Promissory Notes (the “ Notes ”) issued to the Purchasers pursuant thereto. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Purchase Agreement.

 

WHEREAS, subject to the terms and conditions set forth in this Fourth Amendment, the Companies and the Purchasers desire to amend the Purchase Agreement and the Notes as set forth herein;

 

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Fourth Amendment, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Companies and the Purchasers hereby agree as follows:

 

Section 1.           Amendment of Third Amendment; Issuance of Warrants .

 

(a)          By executing below, the Companies and the Purchasers hereby agree to amend Section 1 of that certain Third Amendment to the Purchase Agreement: (i) to remove the following language from such Section 1 in its entirety: “: (i) payment to the Purchasers (on a pro rata basis) of all sums received from the sale of surplus equipment by the Companies (net of sales expenses), such amounts to be applied promptly following sale first to interest accrued on the Notes and not yet paid and then to principal outstanding thereon; and (ii)”; and (ii) to replace the phrase “clause (ii)” in the final parenthetical of the first sentence of such Section 1 with the word “condition”.

 

(b)          As consideration for this Fourth Amendment, the Company shall issue to the Purchasers (on a pro rata basis), promptly upon the execution of this Fourth Amendment, warrants to purchase up to an aggregate of 1,035,715 shares of Common Stock (the “ Warrants ”). The Warrants will have an initial exercise price of $0.28 per share, which is subject to adjustment (including as a result of subsequent financings completed on or prior to June 30, 2014), will be exercisable for a period of five years beginning six months and one day following the issuance of the Warrants, and otherwise have substantially the same terms and conditions as the warrants that were issued to the Purchasers upon the closing of the Purchase Agreement.

 

1
 

 

Section 2.           Amendment of Definitions . The following definitions contained in Section 1.1 of the Purchase Agreement are hereby amended as set forth below:

 

(a)          The definition of “ Transaction Documents ” is hereby amended to add this “Fourth Amendment” as a Transaction Document.

 

(b)          The definition of “ Warrants ” is hereby amended to include the Warrants that may be issued pursuant to this Fourth Amendment.

 

Section 3.           Miscellaneous .

 

3.1            No Other Amendments . Except as otherwise expressly provided by this Fourth Amendment, all of the terms and conditions of each of the Transaction Documents are, and shall continue to be, in full force and effect and are hereby ratified and confirmed in all respects.

 

3.2            Headings . The headings herein are for convenience only, do not constitute a part of this Fourth Amendment and shall not be deemed to limit or affect any of the provisions hereof.

 

3.3            Execution . This Fourth Amendment may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

 

3.4            Severability . If any term, provision, covenant or restriction of this Fourth Amendment is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

3.5            Choice of Law . This Fourth Amendment shall be governed by and construed and enforced in accordance with the internal laws of the State of New York without regard to the principles of conflicts of laws thereof.

 

2
 

 

3.6            Effectiveness . This Fourth Amendment shall be effective upon the Companies execution and receipt of the same amendment executed by all of the undersigned.

 

[Remainder of Page Intentionally Left Blank; Signature Pages Follow]

 

3
 

 

IN WITNESS WHEREOF, the parties hereto have caused this Fourth Amendment to Note and Warrant Purchase Agreement and Secured Promissory Notes to be duly executed by their respective authorized signatories as of the date first indicated above.

 

  MARINA BIOTECH, INC.
     
  By: /s/ J. Michael French
  Name: J. Michael French
  Title: President and Chief Executive Officer
     
  MDRNA RESEARCH, INC.
     
  By: /s/ J. Michael French
  Name:  J. Michael French
  Title: President
     
  CEQUENT PHARMACEUTICALS, INC.
     
  By:  /s/ J. Michael French
  Name: J. Michael French
  Title: President

 

[Remainder of page intentionally left blank; signature pages for Purchasers follows]

 

4
 

 

[PURCHASER SIGNATURE PAGES TO FOURTH AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT and SECURED PROMISSORY NOTES]

 

IN WITNESS WHEREOF, the undersigned have caused this Fourth Amendment to Note and Warrant Purchase Agreement and Secured Promissory Notes to be duly executed by their respective authorized signatories as of the date first indicated above.

  

  GENESIS CAPITAL MANAGEMENT, LLC
     
  By: /s/ Shawn Rhynes
  Name:  Shawn Rhynes
  Title: Managing Director

 

 

5
 

 

[PURCHASER SIGNATURE PAGES TO FOURTH AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT and SECURED PROMISSORY NOTES]

 

IN WITNESS WHEREOF, the undersigned have caused this Fourth Amendment to Note and Warrant Purchase Agreement and Secured Promissory Notes to be duly executed by their respective authorized signatories as of the date first indicated above.

 

  PEAK CAPITAL ADVISORY LIMITED
     
  By: /s/ Feng Bai Ye
  Name:  Feng Bai Ye
  Title: Managing Director

 

6

 

 

LEASE TERMINATION AGREEMENT

 

THIS LEASE TERMINATION AGREEMENT (this “ Agreement ”) is entered into effective as of October 1, 2012 (“ Effective Date ”) by and between DITTY PROPERTIES LIMITED PARTNERSHIP , a Washington limited partnership (“ Landlord ”); and MARINA BIOTECH, INC. , a Delaware corporation, f/k/a MDRNA, Inc., f/k/a Nastech Pharmaceutical Company, Inc. (“ Tenant ”).

 

RECITALS

 

A.            Landlord and Tenant are parties to that certain Lease Agreement dated March 1, 2006 and amended July 17, 2006 (as amended from time to time, the “ Lease ”) under which Tenant leased space located at 3830 Monte Villa Parkway, Bothell, Washington as further described in the Lease (the “ Premises ”).

 

B.            Tenant’s obligations under the Lease are supported by Wells Fargo Bank’s Irrevocable Letter of Credit No. NZS568195 dated March 29, 2006 (as amended from time to time, the “ Letter of Credit ”).

 

C.            Tenant has asked Landlord to release Tenant from its obligations under the Lease prior to the scheduled expiration date. Landlord is willing to terminate the Lease on the terms and conditions of this Agreement.

 

AGREEMENT

 

In consideration of the mutual terms, covenants and conditions set forth herein, Landlord and Tenant hereby agree as follows:

 

1.          Rent Payments; Draws on Letter of Credit; No Obligation to Pay Further Rent. Concurrently with the execution and delivery of this Agreement by all parties hereto, Tenant will pay to Landlord $155,000 as rent for the Premises for the month of October 2012. Thereafter, Tenant’s obligation to pay further rent under the Lease (“ Rent ”) will be satisfied through the Letter of Credit. Landlord will draw the amount of each month’s Rent by drawing on the Letter of Credit on or about the first day of each month from November 2012 through February 2013. In addition, with the drawing of the February 2013 Rent, Landlord will draw the entire remaining amount available to be drawn on the Letter of Credit when it draws the February 2013 Rent. Landlord will be entitled to receive and retain all amounts paid by Tenant or drawn from the Letter of Credit as provided in this Agreement. Notwithstanding anything to the contrary in the Lease, Tenant will have no obligation to increase the amount of the Letter of Credit for amounts drawn by Landlord. Tenant will have no obligation to pay any Rent under the Lease after the date of this Agreement except as provided in this paragraph.

 

1
 

 

2.          Issuance of Stock in Tenant . As additional consideration for the early termination of the Lease, Tenant agrees that, contingent upon and immediately prior to the first to occur of any of the following events, Tenant will issue to Landlord 1,500,000 shares of the common stock of Tenant (“Shares”): (i) the closing by Tenant of an equity financing in a transaction or series of related transactions where such financing yields gross proceeds to Tenant of at least $4,000,000 in the aggregate, including amounts converted under any convertible promissory notes; (ii) a merger of Tenant with or into another entity if the combined market cap of the merging entities is at least $18,000,000 or, if not, upon the market cap of Tenant as the surviving entity of a merger being at least $18,000,000 at any time after the merger; (iii) a sale of all or substantially all of Tenant’s assets; or (iv) a sale of Tenant’s stock after which sale a majority of the outstanding equity of Tenant is held by persons or entities who were not shareholders of Tenant prior to the sale. Tenant represents and warrants to Landlord that, upon such issuance, such stock will be duly authorized, fully-paid and non-assessable and issued in accordance with all applicable laws and regulations. Tenant further represents and warrants that it has provided Landlord with complete and accurate information regarding the Shares and Tenant’s company in order to allow Landlord to decide whether or not to accept the Shares as additional consideration for the release contemplated herein, and has provided the Landlord with all information requested by the Landlord in that regard.  No statement made to the Landlord by the Tenant, or any officer, director, affiliate or representative of the Landlord with respect to such information about the Tenant and the Shares contained any untrue statement of a material fact or omitted to state a material fact necessary to make such statements, in light of the circumstances under which they were made, not misleading. Landlord acknowledges that the Shares constitute unregistered shares of common stock issued by Tenant, and that the sale of the Shares by the undersigned is restricted under state and federal securities laws, including, without limitation, the Securities Act of 1933, as amended (the “ Securities Act ”), and the rules and regulations promulgated thereunder. Landlord agrees that it shall not sell the Shares unless the Shares have been registered under the Securities Act, or unless such sale is permitted under, and is effected in compliance with, an exemption from registration contained in applicable state and federal securities laws, including Rule 144 promulgated under the Securities Act (as such rule may be amended from time to time). For the avoidance of doubt, the parties acknowledge that under Rule 144 as in effect on the date hereof, in general, non-affiliates of the Tenant may effect unlimited public resales of the Shares after six (6) months provided that current public information about the Tenant is available and after twelve (12) months irrespective of the availability of current public information, and affiliates of the Tenant may effect public resales of the Shares after six (6) months provided that current public information about the Tenant is available and subject to volume limitations, manner of sale requirements for equity securities and the filing of a Form 144. Landlord further represents to Tenant that it: (i) either (x) is an “accredited investor” as that term is defined in Regulation D promulgated under the Securities Act or (y) has sufficient knowledge and experience in financial and business matters such that he/it is capable, either alone, or together with his/its advisors, of evaluating the risks and merits of acquiring the Shares; (ii) has the requisite power and authority to enter into and to perform its obligations under this Agreement; (iii) can bear the risk of losing his/its entire investment in the Shares; (iv) understands that current public information about the Tenant is not available as of the date of this Agreement, and may never be available, such that the availability of the exemption from the registration requirements of the Securities Act provided by Rule 144 would be limited, delayed or eliminated; and (v) has been given the opportunity to ask questions of, and receive answers from, the Tenant concerning the Shares and the business of the Tenant, and to obtain such additional information as Landlord deemed necessary in connection with the transactions contemplated by this Agreement.

 

2
 

 

3.          Termination. Subject to the provisions of Section 4 of this Agreement for an Early Termination Date, the Lease will terminate effective at 12:01 a.m. on March 1, 2013 (the “ Termination Date ”) with the same force and effect as if it had terminated on its scheduled termination date. Landlord may reenter the Premises on the Termination Date and Tenant shall have no further rights to use or occupy the Premises on or after the Termination Date. As additional consideration for the early termination of the Lease, Tenant hereby conveys to Landlord all of Tenant’s right, title and interest in and to any personal property, furniture, fixtures and equipment that Tenant does not remove from the Premises and that is remaining in the Premises on the Termination Date (“ Tenant’s Property ”). Tenant represents and warrants that it has the right, title and authority to transfer Tenant’s Property to Landlord and that Tenant’s Property is paid for in full and is not subject to any liens, claims or security interests.

 

4.          Marketing of Premises; Early Termination Date . Landlord will have the right to market and show the Premises for lease to any prospective new tenant at any time from and after the execution and delivery of this Agreement. If reasonably necessary or appropriate to accommodate a new tenant for the Premises, Landlord may give Tenant not less than ten (10) days’ prior written notice that Landlord elects to set a date after September 30, 2012, but earlier than March 1, 2013, as the Termination Date (such earlier date, an “ Early Termination Date ”). In such event, the Early Termination Date shall be the Termination Date for all purposes of this Agreement. Landlord shall be entitled to immediately draw all remaining amounts under this Agreement on the Letter of Credit in the event of an Early Termination.

 

5.          Attorneys’ Fees. If any action or proceeding is brought to interpret or enforce the terms of this Agreement, the prevailing party shall be entitled, in addition to all other damages, to an award of reasonable attorneys’ fees and costs and court costs against the other party.

 

6.          Release. As additional consideration for the mutual agreements set forth herein, Tenant and Landlord make the following releases:

 

a.           Tenant’s Release of Landlord. Tenant hereby releases, waives, discharges, abandons, settles and forever gives up any and all claims, legal or equitable rights, actions or causes of action and all claims or counterclaims which could have been asserted against Landlord, including but not limited to claims that Tenant now has or may have in the future against Landlord, and its related companies, partnerships, and affiliates, and against Landlord’s members, officers, directors, shareholders, general partners, limited partners, insurers, agents, attorneys, employees, successors and assigns, and each of them, both past and present, whether known or unknown, whether discovered or undiscovered at this time and whether contingent or vested, arising from or related in any way to the Lease or Tenant’s occupancy or use of the Premises, except that Tenant does not release Landlord from any obligations arising under this Agreement.

 

3
 

 

b.           Landlord’s Release of Tenant . Effective as of the Termination Date, Landlord releases, waives, discharges, abandons, settles and forever gives up any and all claims, legal or equitable rights, actions or causes of action and all claims or counterclaims which could have been asserted against Tenant, including but not limited to claims that Landlord now has or may have in the future against Tenant, and its related companies, partnerships, and affiliates, and against each of Tenant’s members, officers, directors, shareholders, general partners, limited partners, insurers, agents, attorneys, employees, successors and assigns, and each of them, both past and present, whether known or unknown, whether discovered or undiscovered at this time and whether contingent or vested, arising from or related in any way to the Lease or Tenant’s occupancy or use of the Premises, except that Landlord does not release Tenant from: (i) any obligations arising under this Agreement; and (ii) any obligations other than rent under the Lease that survive termination of the Lease according to the terms of the Lease.

 

7.          Cooperation in Execution of Documents . The parties agree to cooperate in the drafting and execution of any documents necessary and appropriate to effectuate the parties’ agreement herein. Tenant agrees that it will execute a confession of judgment and a stipulated order issuing a writ of restitution promptly upon request, to be effective as of the Termination Date.

 

8.          Legal Representation. Tenant acknowledges that it has been represented, or has had an opportunity to obtain the representation of counsel with respect to this Agreement. Tenant represents to Landlord that it has read and understood the terms hereof and the consequences of executing this Agreement and that no representations have been made to induce the execution of this Agreement. Tenant waives any right it may have to require the provisions of this Agreement to be construed against the party who drafted the same.

 

9.          Authority. Each person signing this Agreement on behalf of one of the parties represents and warrants that he or she is authorized to execute and deliver this Agreement, and that upon such person’s execution hereof, this Agreement will become binding upon such party.

 

10.         Submission Not an Offer. Tenant acknowledges and agrees that submission of this Agreement to it for review and execution is not an offer and that this Agreement shall not be effective until it has been fully executed and delivered by all parties. Tenant further acknowledges that Landlord may not enter into this Agreement unless and until Landlord’s lender has consented in writing to the terms of this Agreement.

 

11.         Miscellaneous. This Agreement sets forth the entire understanding between Landlord and Tenant with respect to the subject matter hereof and replaces all prior or contemporaneous oral or written agreements or understandings. This Agreement shall be construed and governed in accordance with the laws of the State of Washington.

 

12.         Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same instrument.

 

[ signatures on following page ]

 

4
 

 

DATED as of the day and year first written above.

 

LANDLORD:

 

DITTY PROPERTIES LIMITED PARTNERSHIP ,

a Washington limited partnership

 

By: Ditty Properties Incorporated, a Washington

corporation, its general partner

 

By: /s/ Kirk Mathewson
R. Kirk Mathewson, President

 

TENANT:

 

MARINA BIOTECH, INC. , a Delaware corporation

 

By: /s/ J. Michael French
Name:   J. Michael French
Title: President

 

5